Journal Club Review: Long-Term Safety of Guselkumab in Patients with Psoriatic Disease

Join Amber Hudgins, PharmD, a pharmacist specializing in rheumatology and specialty pharmacy at Novant Health in Winston-Salem, North Carolina, as she provides a concise yet insightful review of the long-term safety of Guselkumab in patients with psoriatic disease, including psoriasis and psoriatic arthritis.This discussion highlights a comprehensive integrated analysis of 11 Phase 2 and Phase 3 clinical studies, which pooled over 10,000 patient-years of follow-up data. The results reinforce Guselkumab’s favorable safety profile, demonstrating low rates of severe adverse events, infections, and malignancies, which remained consistent across diverse patient subgroups. Furthermore, adverse event rates during treatment were comparable to those observed during placebo-controlled periods, solidifying Guselkumab as a low-risk, well-tolerated option for long-term management of psoriatic disease.Visit the RhAPP website or explore additional educational content on the RhAPP ACE App.